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The ex Vivo Correlate of the
Antithrombotic Action of Heparin
H. C. HEMKER, S. BEGUIN, J. PIETERS,
AND T. LINDHOUT
Department of Biochemistry
Uniuersity of Limburg
Maastricht. The Netherlands
The advent of low-molecular-weight heparins (LMWH) made it surprisingly clear
how little we know about the connection between the antithrombotic potency of
heparin and its (bio)chemical properties. Classical unfractionated heparin (UFH)
has been shown to be an acceptable antithrombotic, although the bleeding risk
that it may induce is not negligible. More than half a century of clinical trial and
error, often of a type that would not stand up to modern ethical and scientific
standards, have been necessary to find an acceptable dosage scheme. We simply
cannot think ofrepeating the same procedure with each new type ofheparin that
is introduced. Therefore, we have to compare new heparins with the classical
preparations on the basis of laboratory tests. Given this situation, it is slightly
awkward that we do not know what the laboratory properties of heparin are that
indicate its antithrombotic or hemorrhagic activities. The search for the proper
laboratory correlate to in viuo antithrombotic action has occupied us for the last
few years. We feel that this subject is a central one in heparin research. Only.if we
know what tests in the laboratory reflect the action of heparins in a patient, can we
attempt to answer the three crucial questions that are posed by these drugs:
1. What tests are suitable for controlling the quality of heparin therapy in a
patient?
2. How can different types of heparin be standardized, i.e', what amount of
LMWH is the functional equivalent of I U of standard heparin?
3. What laboratory tests indicate the antithrombotic potency of an unknown
heparin?
The ultimate answer to the question of the ex uiuo correlate to in uiuo action
cannot come from the laboratory alone, because the proofofthe heparin pudding
will always remain in the clinical eating. Yet on the basis of laboratory studies, we
can exclude certain possibilities. If, for instance, it can be demonstrated that the
anti-factor Xa action of UFH does not play a role in the thrombin generation in
plasma, then it is highly unlikely that anti-factor Xa activity could relate to anti-
thrombotic activity. Therefore, on the basis of laboratory results one can make an
educated guess and put forward hypotheses on the mode of action of heparin in
uiuo and hence on the laboratory correlate to that.
Is the Conelate To Be Found in the Coagulation System?
One may well argue that the antithrombotic action of heparins does not neces-
sarily have anything to do with its action on blood coagulation. In fact, many
actions of heparin are known apart from its effects on the blood coagulation
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system.l-7 It has, for instance, been described that heparin fractions with a low
affinity to antithrombin III (ATIII) and consequently with a limited effect on blood
coagulation potentiate the effect ofhigh-affinity fractions.E Such findings need not
automatically indicate a mode of action of heparin that bypasses the coagulation
system. As soon as plasma forms part of the reaction medium, especially when it
contains or has contained activated platelets, various heparin-neutralizing pro-
teins are present. Heparins with a low affinity to ATIII may still have a high
affinity to heparin-neutralizing proteins. If such heparins bind to neutralizing
factors, they will automatically cause an increased availability of heparins with a
high ATIII affinity.
One argument pretty well excludes the possibility that the anticoagulant prop-
erties of heparins have nothing to do with their antithrombotic action: a com-
pletely different family of anticoagulant drugs, the vitamin-K-antagonist coumarin
congeners, are also good antithrombotics. These oral anticoagulants, like heparin,
have several effects that are not related to blood coagulation, but these are com-
pletely different from the noncoagulation effects of heparin (for a review, see
ref. 9).
The only action that, to our knowledge, coumarin congeners have in common
with heparin is their anticoagulant action. Against this argument one can make the
point that a third recognized antithrombotic, viz., aspirin, has no anticoagulant
properties.lo This is certainly true if one investigates platelet-poor plasma. In
platelet-rich plasma, however, the procoagulant action of platelets can be inhib-
ited by aspirin.rrThis leaves open the possibility that in this case also inhibition of
thrombin formation is the essential mode of action of the drug, whether it be
mediated by inhibition of cyclooxygenase or not.
We conclude that for the moment it is reasonable to assume that the antithrom-
botic action of heparin is related to its antithrombin action.
Is Factor Xa Inhibition the Laboratory Conelate to Antithrombotic Action?
When evidence was produced suggesting that LMWH might be as good an
antithrombotic agent as UFH is and at the same time induce a lesser bleeding risk,
it was logical to think that the yardstick for the safety of a heparin was to be found
in a property that was different in both types of heparin. Such a property was
found to be the relative anti-factor Xa potency. LMWHs with decreasing chain
length gradually loose their antithrombin action, but to a certain extent retain their
anti-factor Xa action. It was therefore thought that the anti-factor Xa action
indicated the antithrombotic properties and that antithrombin activity parallels
the bleeding risk. 12-20
For some time it therefore has been thought that anti-factor Xa action was a
crucial property of all heparins. In the last few years this proposition has been
doubted on various grounds.2l-27 It is surprising to see that in fact the ratio be-
tween the antithrombin potency of LMWH and its antifactor Xa potency does not
differ significantly from that of UFH in a purified system (Tarle l). On the other
hand, the difference does appear when anti-factor Xa units are determined by the
standard procedure, i.e., by measuring the decay of added factor Xa in plasma.
The setup that uses whole plasma probably approaches the in uiuo situation better
than the purified system does, but still the addition of a large amount of isolated
factor Xa far from mimicks physiological conditions.
We approached the question by measuring the functional factor Xa activity in
clotting plasma in a situation as close as possible to the situation in uiuo. We
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TABLE 1. Breakdown Constants of Various Clotting Proteases with Different
Heparins in a Purified Systemo
Heparins IIa IXa Xa XIa IIa/Xa
4.1 0.021 9.4
0.8 0.002 9.1
0.27 0.001 10.6
0.45 0.002 4.2
tr.4 0.003 0
1.3 0.006 tl.4
0.4 0.001 0
" Values are in min-r (p,g heparin/ml)-l
developed a method that allows calculation of the activity of prothrombinase in
clotting plasma.2t Prothrombinase is the complex of factor Xa and factor Va
adsorbed onto procoagulant phospholipid, only in this complex factor Xa acquires
kinetic properties that enable it to activate prothrombin at physiologically rele-
vant velocities.2e
It is known that factor Xa, when functioning in prothrombinase, is protected
from antithrombin III and heparin action by phospholipid and factor Va.30-3E The
burst of prothrombinase activity in plasma is short because the available pro-
thrombin in clotting plasma exhausts rapidly. We wanted to know whether pro-
thrombinase in clotting plasma during the time that it actually produces thrombin
is inhibited by heparin. We reasoned that at any moment the velocity of observed
thrombin generation is the sum of the velocities of prothrombin conversion and of
thrombin breakdown (Frc. 1). We showed that thrombin breakdown is a pseudo-
first-order process with a breakdown constant that does not change during the
time course of the thrombin generation curye.2E This means that at any point of
the curve we can calculate the velocity of thrombin breakdown if we know the
concentration of free thrombin. The formation of the amidolytically active a2-
macroglobulin-thrombin complex complicates the algorithm but does not invali-
date the approach. The calculations are readily carried out by a personal com-
puter. By applying this method it is possible to obtain the time course of
prothrombinase activity from the thrombin generation curve' This curve gives
more important information than the course of factor Xa activity, in the sense that
it gives the factor Xa activity Only insofar as it is involved in prothrombin conver-
sion.
When we computed prothrombinase activity in the presence of various con-
centrations of heparin, it appeared that heparin concentrations inhibited the ob-
served velocity of thrombin generation for up to 85Vo, but would not inhlbit
prothrombinase (FIc. 2). This means that, for all practical purposes heparin does
not inhibit factor Xa insofar as it is active in prothrombin conversion but scav-
enges the thrombin formed. This already clearly indicates that anti-factor Xa
action cannot be the ex uiuo property we are looking for, because heparin is a
good antithrombotic and yet has no anti-prothrombinase activity to speak of.
Clotting factors activated in situ tend to have properties that differ from isolated
clotting proteases. This holds not only for factor Xa but also for thrombin. In
general, the breakdown constants of endogenous thrombin in plasma are lower
than those found with the purified protease.
To our surprise, two low-molecular-weight heparins were found to act primar-
ily on thrombin, just like UFH. Two very low molecular weight heparins; the
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PK 10169
cY 216
cv 222
Pentasaccharide
EMT 966
EMT 967
38.7 0.180
7 .3 0.109
2.E7 0.101
1.91 0.05E
0 0.032
14.8 0.15E
0 0.020
HEMKER et aI.: ANTITHROMBOIIC ACTION 149
:
(,
6
c
.o
E
o
c
F
o
Tlme
FIGURE 1. The analysis of the thrombin generation curve. Line A is the experimentally
our"iu"a amidolytic thrombin activity (I). Line B represents the activity of the a2-macro-
gr"u"rir thiombin complex (M). Atany given moment (s), the amount of free thrombin (F)
ian be calculated [r' = T - Ml. Then the breakdown velocity of thrombin can be found
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FIGURE 3. The relation between inhibition of thrombin generation and prothrombinase
activity. The inhibition obtained with various concentrations of different heparins on the
extrinsically triggered thrombin generation curve is plotted against the inhibi-tion of the peak
of the prolhrombinase curve. The heparin concentrations were 0.05-1.2 ,rg pentasac-
charideinrl (A); 0.05-1.2 s,g PK 10169/ml (O); 2'5-l'0 F.eCY 2l6lml (I); and 0'06-0'6 pg
unfractionated heparin/ml (O).
amount : 12 nM). The first traces of factor Xa formed therefore suffice to obtain
all the prothrombinase that is necessary. The activation of factor V seems to be
the rate-limiting step (FIc. 4).
When we start coagulation via the intrinsic system (Flc. 5), e.g., with kaolin'
we then see a clearcut lag time before thrombin generation starts. In the presence
TABLr' 2. IC5s Values of Different Heparins in Platelet-Poor Plasmaa
Thrombin
Generation
PTase
Generation
UFH
Fraxiparine
cv 222
Pentasaccharide
Enoxaparine
Fraction A
Fraction B
0.25
2.5
2.0
0. l0
0.6
0.2s
l0
1 .2
>>10
>>10
0. l0
> 5
)
t0
, Values are in pglml. One unit of unfractionated heparin (UFH) roughly equals 6 pg.
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of heparin these lag times are prolonged. Addition of preactivated factor VIII or
addition of nanomolar amounts of thrombin to the plasma prior to starting the
reaction abolishes this lag time. This is a direct indication that heparins also can
inhibit prothrombinase formation by inhibiting the positive feedback activation of
factor VIII by thrombin.
It is interesting to see that in intrinsic coagulation the amount of prothrom-
binase decreases when heparin is added. This cannot be attributed to factor Xa
inactivation to a larger extent than in the extrinsic system because, as soon as the
system is started with the factor X activating complex, the inhibition disappears.
It must therefore be due to a decrease of the amount of tenase that is available.
The formation of tenase depends on factor IXa and factor VIIIa generation. It has
been demonstrated that the activation of factor IX is not inhibited by heparin.
Thus, like the formation of the prothrombinase complex, it is reasonable to as-
FIGURE 6. The influence of unfractionated heparin on thrombin generation in platelet-rich
plasma. Experimental conditions as in Frcune 2 but for the use of platelet-iich olasma
(3 x 108 platelets/ml) and human brain thromboplastin i  a dilution of l:400. The heparin
concentrations were none (A); 0.1 u/ml (o); and 0.3 U/ml (a). The low-molecular-wLight
heparin CY 216 (O) was present at 0.07 anti-Ila U/ml.
sume that formation of the factor-X-activating complex largely depends on the
generation of the cofactor, factor vIIIa. Because thrombin is the main activator of
factor vIII, low tenase concentrations might be explained by the heparin-medi-
ated scavenging of thrombin. Alternatively, inactivation of noncomplexed factor
IXa might also explain the reduced generation of tenase when heparin is present.
The Action of Heparins in Platelet-Rich Plasma
Thrombin generation in platelet-rich plasma (PRP) is an in uitro system that is
one step nearer to physiological reality than thrombin generation in platelet-poor
plasma (PPP). As we did not find essential differences between the mode of aition
of UFH and several LMWHs in platelet-poor plasma, it was a logical step to study
platelet-rich plasma next.
Thrombin generation in PRP differs essentially from that in ppp in that it
always shows a burst of thrombin formation after aragtime (Frc. 6). If no external
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trigger is added the lag phase lasts 10-12 minutes. Trace amounts of thromboplas-
tin (final dilution in the system, l:2400) shorten this lag by 3-5 minutes. These
concentrations of thromboplastin are without effect on PPP. We could show that
the thrombin burst is caused by the production ofprocoagulant phospholipids by
the platelets. Nanomolar amounts of thrombin generated during the lag time are
instrumental in triggering the platelets.
All substances that inhibit thrombin formation or lower the ambient thrombin
inhibited thrombin appearance in PPP (Ftc. 2).
On the other hand, the low-molecular-weight heparins are less subject to PF 4
neutralization than UFH. A typical example is shown in FIcunr 6. Fraxiparine,
which is equally effective on the basis of anti-Ila U/ml in platelet-poor plasma
when compared with UFH, does inhibit the thrombin generation in platelet-rich
plasma much more effectively than UFH.
Summary, Conclusion, and a Hypothesis
The low-molecular-weight heparins that we have tested and that are available
for treatment of patients act upon the coagulation of platelet-poor plasma in
essentially the same way as standard heparin. Most, like UFH, do have a slight
anti-prothrombinase action that becomes evident at higher concentrations. Very
low molecular weight heparins that lack antithrombin activity retain their antipro-
thrombinase action, however.
The fact that most heparins have primarily an antithrombin action does not
mean that they would not work on thrombin generation too. Both from our work
and from that of others it appears that the product activation by thrombin is an
essential feature ofthe natural clotting mechanism at least at three levels: platelet
activation, factor V activation, and factor VIII activation. Both UFH and LMWH
act primarily by inhibiting these feedback loops. We found only quantitative
differences between the mode of action of commercially available LMWHs and
UFH on this mechanism.
However, an essential difference between LMWH and UFH is their suscepti-
bility to inactivation by PF 4. Fully activated platelets at 3 x 108 ml-r are capable
of nlutralizing UFH concentrations that can almost completely inhibit thrombin
formation in platelet-poor plasma. LMWH is neutralized to a much lesser extent.
we hypothesize that this difference in PF 4 susceptibility explains much of the
difference between LMWH and UFH. Thrombin generation in platelet-rich
plasma is putatively the best predictor of in uiuo antithrombotic action'
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